Innovating Clinical Trials

ICT Ep 2.40: Duncan Shaw on the AI Translation Trap: Why the Human “Last Mile” Still Matters When the Stakes Are High (Part 3/3)

In Part 3 of this three-part conversation, Liam and Ted wrap up their discussion with Duncan, President at DTS Language Services about AI, risk mitigation, and the human

ICT Ep 2.39: Duncan Shaw on the Translation “Quilt Factor”: How Inconsistency Can Erode Patient Trust and Derail Trial Operations (Part 2/3)

In Part 2 of this three-part conversation, Liam and Ted continue their discussion with Duncan, President at DTS Language Services about patient trust, consistency, and th

ICT Ep 2.38: Duncan Shaw on the Hidden Risks of Clinical Trial Translation: What Happens With One Wrong Word (Part 1/3)

In Part 1 of this three-part conversation, Liam and Ted sit down with Duncan, President at DTS Language Services, to talk about the good, the bad, and the ugly of clinica

ICT Ep 2.37: "You Lose a Patient You Didn't Even Know You Lost" Why No One Owns Recruitment

In this episode, Ted introduces the “ENROLL Corporation” (Everyone Needed for Recruitment Optimization Leadership and Logistics) an imaginary joint venture owned by the s

ICT Ep 2.36: Robin Piazza on ICH E6 R3 and the New Rules for Safety Oversight (Part 2/2)

In Part 2, Robin Piazza, Liam and Ted get specific about what good safety oversight actually looks like in practice,  and what sponsors are getting wrong under the shift

ICT Ep 2.35: Robin Piazza on the Safety Oversight Gap No One's Training For (Part 1/2)

Robin Piazza reached out to us directly with this topic suggestion, and we’re glad she did. In Part 1 of this two-part conversation, Liam and Ted sit down with Robin, Fou

ICT Ep 2.34: Study Startup Delays Are a Symptom: What Happens When You Stop and Listen

In this episode, Liam and Ted ask a simple “what if”, what if the industry took the time to really listen?  Ted starts with a study startup delay that looks like a tooli

ICT Ep 2.33: Steve Wimmer on the Button That Almost Killed a Recruitment Campaign (Part 3/3)

Each episode in this series has built toward this one: what does all of this look like from the other side of the table?  In the final part of this series, the Steve Wim

ICT Ep 2.32: Steve Wimmer on Why Recruitment Campaigns Fall Apart at the Site (Part 2/3)

Part 1 was about why storytelling matters, part 2 is about how to actually operationalize it and Steve Wimmer brings a framework that reframes the entire recruitment funn

ICT Ep 2.31: Steve Wimmer on Why Storytelling Is What Sponsors Keep Getting Wrong (Part 1/3)

Liam and Ted sit down with Steve Wimmer, who brings seven years of direct-to-patient recruitment advertising experience. They discuss why storytelling in clinical trial r

Ep 2.30: Scott Burgher on Where AI Actually Helps Patient Recruitment (Part 3/3)

In the final part of this three-part conversation, Liam and Ted close things out with Scott Burgher, Director of Patient Operations at Quest Diagnostics, looking ahead at

Ep 2.29: "That's Not a Performance Problem, It's a Structural One" Scott Burgher on Why Sites Stop Recruiting (Part 2/3)

In Part 2 of this three-part conversation, Liam and Ted continue with Scott Burgher, Director of Patient Operations at Quest Diagnostics, going deeper into why recruitmen

Ep 2.28 Scott Burgher on Why 86% of Trials Miss Their Enrollment Deadline (Part 1/3)

In Part 1 of this three-part conversation, Liam and Ted sit down with Scott Burgher, Director of Patient Operations at Quest Diagnostics, who brings over 20 years of pati

Ep 2.27: 31 Years of Clinical Trials, Here's What Ted Trafford Knows for Sure

In this special episode, we mark Ted Trafford's 31st year in clinical trials with a candid reflection on what three decades in this industry actually teaches you. I

Ep 2.26: Lasagna's Law and Building Recruitment Forecasts You Can Actually Trust

Every trial starts with a number on a slide,  patients needed, months allotted, a clean straight line on a chart.  Liam and Ted pull that line apart in this episode, sta

Ep. 2.25 The Burdens Still Breaking Clinical Trials: 50-Page Consents, Broken Tech, and Stolen CRCs

In this episode, Ted  opens with a poem that captures the persistent, compounding burden on clinical trial sites: 50-page consents, non-functional tech, poached CRCs, fin

Ep 2.24 The Decision Threshold Matrix: Why Patient Motivation Isn't Fixed and What It Means for Trial Recruitment

In this episode, Liam and Ted explore one of the most underexamined problems in clinical trial recruitment: patient motivation is not static.  Drawing on real-world expe

Ep 2.23: Jill Fikowski on Why Participants Drop Out and What to Do About It (3/3)

In the final episode of our three-part series with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into one of the most persistent problems in

Ep 2.22: Jill Fikowski on Designing Trials That Communities Actually Want to Join (2/3)

In Part 2 of our conversation with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into what good community engagement actually looks like in p

Ep 2.21: Jill Fikowski on on Substance Use, Stigma, and the Research That Actually Changed Policy (1/3)

Jill Fikowski, founder and CEO of Changemark Research + Evaluation, brings 25+ years of lived and professional experience in substance use and mental health research. In